Marksans Pharma Limited (MARKSANS) Price & Analysis

Compare

5 Followers

MARKSANS Stock Chart & Stats

₹182.05

-₹6.40(-2.21%)

At close: Jan 08 4:00 PM EST

₹182.05

-₹6.40(-2.21%)

Day’s Range― - ―

52-Week Range₹157.25 - ₹270.60

Previous CloseN/A

Volume681.00K

Average Volume (3M)99.03K

Market Cap

₹82.05B

Enterprise Value₹82.00B

Total Cash (Recent Filing)₹7.06B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)22.8

Beta1.67

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.44%

Share Statistics

EPS (TTM)2.50

Shares Outstanding453,163,760

10 Day Avg. Volume119,310

30 Day Avg. Volume99,030

Financial Highlights & Ratios

PEG Ratio1.24

Price to Book (P/B)4.08

Price to Sales (P/S)3.83

P/FCF Ratio298.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And Healthy MarginsSustained double-digit revenue growth and high gross and net margins indicate durable product economics and pricing power. Robust margins support reinvestment in R&D, market expansion and buffer against margin pressure, underpinning long-term profitability and scaling.

Low Leverage And Solid Equity BaseA strong equity ratio and minimal debt provide financial resilience and optionality for strategic moves. Low leverage reduces refinancing and interest risks, enabling capital allocation toward growth or M&A without threatening solvency over a multiyear horizon.

Improved Free Cash Flow From Efficient CapexSignificant FCF improvement signals better capex discipline or working capital management, enhancing funding for debt reduction, product launches or shareholder returns. Strong FCF supports long-term strategic flexibility despite OCF variability.

Bears Say

Operating Cash Flow Weakness And VolatilityA decline in operating cash flow and OCF conversion below 1.0 indicate earnings are not fully converting to cash, reflecting working-capital or collection pressures. Persistent OCF weakness can constrain organic funding for growth and increase reliance on external financing.

Rising Liabilities Warrant MonitoringAlthough leverage is low today, a trend of increasing liabilities could erode the strong equity base and reduce financial flexibility. If liabilities grow faster than cash generation, interest and covenant risk could rise, limiting investment and strategic options.

Revenue Dependence On Regulatory Approvals And Partner OrdersBusiness relies on timely regulatory approvals and partner/distributor purchase orders for launches in higher-value markets. This creates structural timing and execution risk: approval delays or partner failures can materially affect future revenue streams and growth visibility.

Marksans Pharma Limited News

Marksans Pharma Releases Q3 and 9M FY26 Investor Presentation

Marksans Pharma Limited ( ($IN:MARKSANS) ) has issued an update. Marksans Pharma Limited has released its investor presentation...

19d ago

Marksans Pharma Expands Global Footprint With New Subsidiaries in Europe and Canada

Marksans Pharma Limited ( ($IN:MARKSANS) ) has issued an update. Marksans Pharma Limited has strengthened its international footprint...

28d ago

Marksans Pharma’s UK Subsidiary Gains MHRA Approval for Mefenamic Acid Tablets

Marksans Pharma Limited ( ($IN:MARKSANS) ) has provided an announcement. Marksans Pharma Limited announced that its UK-based wholly...

3M ago

Marksans Pharma Releases Unaudited Financial Results for September 2025

Marksans Pharma Limited ( ($IN:MARKSANS) ) has issued an announcement. Marksans Pharma Limited has announced its unaudited financial...

3M ago

Marksans Pharma Advocates Integrity in Vigilance Awareness Week 2025

Marksans Pharma Limited ( ($IN:MARKSANS) ) has shared an update. Marksans Pharma Limited has announced its participation in...

4M ago

Marksans Pharma’s UK Subsidiary Gains Approval for Exemestane Tablets

Marksans Pharma Limited ( ($IN:MARKSANS) ) has shared an update. Marksans Pharma Limited announced that its UK-based subsidiary,...

4M ago

Marksans Pharma Announces AGM Notice Addendum

Marksans Pharma Limited ( ($IN:MARKSANS) ) has issued an announcement. Marksans Pharma Limited has announced an addendum to...

7M ago

Marksans Pharma Appoints New Secretarial Auditor for Five-Year Term

Marksans Pharma Limited ( ($IN:MARKSANS) ) just unveiled an announcement. Marksans Pharma Limited has announced the appointment of...

8M ago

Marksans Pharma to Engage Stakeholders at Upcoming Conference

An announcement from Marksans Pharma Limited ( ($IN:MARKSANS) ) is now available. Marksans Pharma Limited has announced its...

11M ago

Marksans Pharma’s Credit Rating Upgraded by India Ratings

Marksans Pharma Limited ( ($IN:MARKSANS) ) has provided an announcement. Marksans Pharma Limited has announced an upgrade in...

12M ago

MARKSANS FAQ

What was Marksans Pharma Limited’s price range in the past 12 months?

Marksans Pharma Limited lowest stock price was ₹157.25 and its highest was ₹270.60 in the past 12 months.

What is Marksans Pharma Limited’s market cap?

Marksans Pharma Limited’s market cap is ₹82.05B.

When is Marksans Pharma Limited’s upcoming earnings report date?

Marksans Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 98 days.

How were Marksans Pharma Limited’s earnings last quarter?

Marksans Pharma Limited released its earnings results on Feb 05, 2026. The company reported ₹2.5 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.5.

Is Marksans Pharma Limited overvalued?

According to Wall Street analysts Marksans Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Marksans Pharma Limited pay dividends?

Marksans Pharma Limited pays a Annually dividend of ₹0.8 which represents an annual dividend yield of 0.44%. See more information on Marksans Pharma Limited dividends here

What is Marksans Pharma Limited’s EPS estimate?

Marksans Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Marksans Pharma Limited have?

Marksans Pharma Limited has 453,163,760 shares outstanding.

What happened to Marksans Pharma Limited’s price movement after its last earnings report?

Marksans Pharma Limited reported an EPS of ₹2.5 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.555%.

Which hedge fund is a major shareholder of Marksans Pharma Limited?

Currently, no hedge funds are holding shares in IN:MARKSANS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.